ARVN vs SLDB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SLDB Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Solid Biosciences Inc. Common Stock (SLDB) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ARVN counters with relative strength in Valuation. Fundamentally, ARVN trades at 17.9x Forward P/E with -10.1% operating margin (-98.8% YoY revenue) versus SLDB at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ARVN sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against SLDB sits in BREAKDOWN (15th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARVN Revenue | SLDB Revenue | ARVN Op. Margin | SLDB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -306.3% | N/A | ARVN |
| FY2019 | $20M | N/A | -281.4% | N/A | ARVN |
| FY2020 | $20M | N/A | -554.1% | N/A | ARVN |
| FY2021 | $50M | $10M | -403.4% | -530.5% | ARVN |
| FY2022 | $130M | $10M | -200.3% | -1315.2% | ARVN |
| FY2023 | $80M | N/A | -511.5% | N/A | ARVN |
| FY2024 | $260M | N/A | -95.0% | N/A | ARVN |
| FY2025 | $260M | N/A | -45.1% | N/A | ARVN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARVN | SLDB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $449.9M | $781.3M | Larger Scale | SLDB |
| Trailing P/E Ratio Valuation | 17.9x | N/M | Lower Multiple | ARVN |
| Forward P/E Ratio Valuation | 17.9x | N/M | Lower Multiple | ARVN |
| Revenue Growth (YoY) Growth | -98.8% | -100.0% | Higher Growth | ARVN |
| Operating Margin (TTM) Profitability | -10.1% | 0.0% | Higher Margin | SLDB |
| Net Profit Margin Profitability | -3.5% | 0.0% | Higher Margin | SLDB |
| Return on Equity (ROE) Capital Efficiency | -1.8% | -76.9% | Higher ROE | ARVN |
| 52-Week Range Position Momentum | 5% ($6โ$15) | 33% ($4โ$11) | Stronger Trend | SLDB |
| Beta / 30D Volatility Risk Regime | 1.40ฮฒ ยท 66% Vol | 2.14ฮฒ ยท 76% Vol | Lower Realized Risk | ARVN |
| Unified Institutional Score Composite Signal | 52.9 / 100 (HOLD) | 36.5 / 100 (SELL) | Higher Composite | ARVN |